12:29 Mon 20 May 2019
Cello Health PLC - Issue of Equity
("Cello" or the "Company")
Issue of Equity
Further to the announcement released on
To part satisfy the deferred consideration, the Company has applied for the admission of 320,243 new ordinary shares of
Following admission, Cello's issued share capital will consist of 105,545,545 Ordinary Shares, of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company will therefore be 105,092,545 Ordinary Shares.
The above figure (105,092,545 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the
Enquiries:
|
020 7812 8460 |
|
|
|
|
Cenkos Securities plc |
020 7397 8900 |
|
|
|
|
Buchanan Mark Court |
020 7466 5000 |
|
|
|
|
|
|
About
We are a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
We enable clients to differentiate their propositions and drive brand success in ever more complex global markets. We deliver our services through nearly 1,000 highly skilled professionals utilising latest thinking, technology and digital solutions.
For further information, please visit: https://cellohealthplc.com/
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE